Furthermore, our data are in agreement with the fact that p120 is not haplo-insufficient in tumour suppression, and suggest that heterozygous genomic inactivation predisposes to complete loss of p120 expression and subsequent adverse survival of cancer patients. Here, CTNND1 is linked to cancer.